AN2 Therapeutics Reports Q4 Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy ANTX?
Source: seekingalpha
- Earnings Report Disappointment: AN2 Therapeutics reported a Q4 GAAP EPS of -$0.29, missing the expected -$0.24, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves Status: As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $60 million, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Expectations: Given the earnings miss, the market may adopt a cautious stance regarding AN2's growth prospects, prompting investors to closely monitor subsequent strategic adjustments and financial health.
- Analyst Rating Dynamics: According to Seeking Alpha's Quant Rating, AN2 Therapeutics' investment rating may be affected by its financial performance, leading analysts to potentially reassess its future investment value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANTX
Wall Street analysts forecast ANTX stock price to fall
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 3.450
Low
1.00
Averages
1.67
High
2.00
Current: 3.450
Low
1.00
Averages
1.67
High
2.00
No data
About ANTX
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AN2 Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: AN2 Therapeutics reported a Q4 GAAP EPS of -$0.29, missing the expected -$0.24, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves Status: As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $60 million, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Expectations: Given the earnings miss, the market may adopt a cautious stance regarding AN2's growth prospects, prompting investors to closely monitor subsequent strategic adjustments and financial health.
- Analyst Rating Dynamics: According to Seeking Alpha's Quant Rating, AN2 Therapeutics' investment rating may be affected by its financial performance, leading analysts to potentially reassess its future investment value.
See More
AN2 Therapeutics Plans to Sell 8 Million Shares at $2.85 Each
- Private Placement Announcement: AN2 Therapeutics plans to sell 8.25 million shares of common stock at $2.85 each, aiming to raise approximately $40 million, with participation from institutional investors like Coastlands Capital, Commodore Capital, and Vivo Capital, indicating strong market confidence in its blood cancer treatment.
- Stock Surge: Following the announcement of positive clinical results for its blood cancer drug epetraborole, AN2 Therapeutics' stock has skyrocketed over 500% in four trading sessions, with a more than 110% increase on Monday alone, marking the largest single-day gain in its history and reflecting investor optimism about future developments.
- Clinical Trial Progress: The company plans to initiate a Phase 2 clinical trial for patients with Polycythemia Vera in Q3 2026 and expects to provide initial trial updates in the following quarter, potentially validating the drug's efficacy and safety, which could enhance the company's market performance.
- Market Sentiment Analysis: Retail sentiment on Stocktwits has remained extremely bullish over the past 24 hours, with high message volumes, as some users speculate the stock could rise to $108, although others express confusion over the bullish excitement, indicating mixed views in the market regarding the stock's future trajectory.
See More
AN2 Therapeutics Shares Surge After $40 Million Financing Announcement
- Significant Financing: AN2 Therapeutics announced a $40 million private placement financing, selling 8,245,611 common shares at $2.85 each, along with pre-funded warrants, expected to close on March 10, significantly enhancing the company's financial strength to support R&D.
- Strong Stock Performance: Following the financing announcement, AN2 Therapeutics shares surged 93.68% to $5.52, reaching a new 52-week high, indicating strong market confidence in the company's future and positive investor sentiment.
- Diverse R&D Pipeline: AN2 Therapeutics is developing small molecule therapies based on its boron chemistry platform targeting various diseases, including polycythemia vera, nontuberculous mycobacterial lung disease, Chagas disease, and melioidosis, showcasing the company's broad focus in infectious and rare diseases.
- Optimistic Market Outlook: With the successful financing, AN2 is poised to accelerate its R&D efforts, particularly in early-stage oncology and infectious disease research, further enhancing its competitiveness and market position in the biopharmaceutical industry.
See More
AN2 Therapeutics Secures $40M Private Placement Financing
- Financing Size: AN2 Therapeutics announced a $40 million private placement financing, involving the sale of approximately 8.25 million shares at $2.85 each, along with pre-funded warrants for up to 5.79 million shares at $2.84999 each, which will provide essential funding for the company's R&D and operations.
- Use of Funds: The proceeds from this financing are expected to primarily support the company's research and development projects and daily operations, ensuring that AN2 Therapeutics remains competitive in the clinical-stage biopharmaceutical development, thereby facilitating the market introduction of its products.
- Transaction Timeline: The private placement is expected to close on March 10, 2026, providing the company ample time to optimize the use of funds and advance its projects, ensuring positive progress in future clinical trials.
- Market Reaction: Following the announcement of the financing, AN2 Therapeutics' stock price traded 3% higher during pre-market trading on Monday, indicating a positive market reaction to the financing plan, which may enhance investor confidence in the company's future growth.
See More
AN2 Therapeutics Partners with GSK to Develop Boron-Based LeuRS Inhibitors for Tuberculosis Treatment
Funding and Collaboration: AN2 Therapeutics has received a third year of funding from the Gates Foundation to support its collaboration with GSK in developing new therapies for tuberculosis (TB), a significant global health issue affecting over a quarter of the world's population.
Boron Chemistry Platform: The company utilizes a unique boron chemistry platform for drug discovery, which allows for the design of compounds targeting novel mechanisms, potentially leading to breakthroughs in treating infectious diseases and oncology.
Commitment to TB Treatment: Both AN2 and GSK emphasize their commitment to addressing the urgent needs of TB patients, particularly in lower-income countries, through innovative scientific approaches and strong partnerships.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the potential success of their collaboration and the development of new therapeutics, acknowledging the inherent risks and uncertainties involved in drug discovery and regulatory processes.
See More
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
Collaboration for Chagas Disease Treatment: AN2 Therapeutics and DNDi are collaborating to advance the clinical development of AN2-502998, an oral drug candidate with potential to cure chronic Chagas disease, which affects millions globally.
Clinical Trial Plans: Startup activities for a Phase 1 human study of AN2-502998 are underway, with a Phase 2 study expected to begin in 2026, aiming to provide a safer and more effective treatment option for Chagas disease.
See More
AN2 Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: AN2 Therapeutics reported a Q4 GAAP EPS of -$0.29, missing the expected -$0.24, indicating challenges in profitability that could undermine investor confidence.
- Cash Reserves Status: As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $60 million, which, while providing some liquidity, raises concerns about capital efficiency and future financing needs.
- Market Reaction Expectations: Given the earnings miss, the market may adopt a cautious stance regarding AN2's growth prospects, prompting investors to closely monitor subsequent strategic adjustments and financial health.
- Analyst Rating Dynamics: According to Seeking Alpha's Quant Rating, AN2 Therapeutics' investment rating may be affected by its financial performance, leading analysts to potentially reassess its future investment value.
See More
AN2 Therapeutics Plans to Sell 8 Million Shares at $2.85 Each
- Private Placement Announcement: AN2 Therapeutics plans to sell 8.25 million shares of common stock at $2.85 each, aiming to raise approximately $40 million, with participation from institutional investors like Coastlands Capital, Commodore Capital, and Vivo Capital, indicating strong market confidence in its blood cancer treatment.
- Stock Surge: Following the announcement of positive clinical results for its blood cancer drug epetraborole, AN2 Therapeutics' stock has skyrocketed over 500% in four trading sessions, with a more than 110% increase on Monday alone, marking the largest single-day gain in its history and reflecting investor optimism about future developments.
- Clinical Trial Progress: The company plans to initiate a Phase 2 clinical trial for patients with Polycythemia Vera in Q3 2026 and expects to provide initial trial updates in the following quarter, potentially validating the drug's efficacy and safety, which could enhance the company's market performance.
- Market Sentiment Analysis: Retail sentiment on Stocktwits has remained extremely bullish over the past 24 hours, with high message volumes, as some users speculate the stock could rise to $108, although others express confusion over the bullish excitement, indicating mixed views in the market regarding the stock's future trajectory.
See More
AN2 Therapeutics Shares Surge After $40 Million Financing Announcement
- Significant Financing: AN2 Therapeutics announced a $40 million private placement financing, selling 8,245,611 common shares at $2.85 each, along with pre-funded warrants, expected to close on March 10, significantly enhancing the company's financial strength to support R&D.
- Strong Stock Performance: Following the financing announcement, AN2 Therapeutics shares surged 93.68% to $5.52, reaching a new 52-week high, indicating strong market confidence in the company's future and positive investor sentiment.
- Diverse R&D Pipeline: AN2 Therapeutics is developing small molecule therapies based on its boron chemistry platform targeting various diseases, including polycythemia vera, nontuberculous mycobacterial lung disease, Chagas disease, and melioidosis, showcasing the company's broad focus in infectious and rare diseases.
- Optimistic Market Outlook: With the successful financing, AN2 is poised to accelerate its R&D efforts, particularly in early-stage oncology and infectious disease research, further enhancing its competitiveness and market position in the biopharmaceutical industry.
See More
AN2 Therapeutics Secures $40M Private Placement Financing
- Financing Size: AN2 Therapeutics announced a $40 million private placement financing, involving the sale of approximately 8.25 million shares at $2.85 each, along with pre-funded warrants for up to 5.79 million shares at $2.84999 each, which will provide essential funding for the company's R&D and operations.
- Use of Funds: The proceeds from this financing are expected to primarily support the company's research and development projects and daily operations, ensuring that AN2 Therapeutics remains competitive in the clinical-stage biopharmaceutical development, thereby facilitating the market introduction of its products.
- Transaction Timeline: The private placement is expected to close on March 10, 2026, providing the company ample time to optimize the use of funds and advance its projects, ensuring positive progress in future clinical trials.
- Market Reaction: Following the announcement of the financing, AN2 Therapeutics' stock price traded 3% higher during pre-market trading on Monday, indicating a positive market reaction to the financing plan, which may enhance investor confidence in the company's future growth.
See More
AN2 Therapeutics Partners with GSK to Develop Boron-Based LeuRS Inhibitors for Tuberculosis Treatment
Funding and Collaboration: AN2 Therapeutics has received a third year of funding from the Gates Foundation to support its collaboration with GSK in developing new therapies for tuberculosis (TB), a significant global health issue affecting over a quarter of the world's population.
Boron Chemistry Platform: The company utilizes a unique boron chemistry platform for drug discovery, which allows for the design of compounds targeting novel mechanisms, potentially leading to breakthroughs in treating infectious diseases and oncology.
Commitment to TB Treatment: Both AN2 and GSK emphasize their commitment to addressing the urgent needs of TB patients, particularly in lower-income countries, through innovative scientific approaches and strong partnerships.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the potential success of their collaboration and the development of new therapeutics, acknowledging the inherent risks and uncertainties involved in drug discovery and regulatory processes.
See More
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
Collaboration for Chagas Disease Treatment: AN2 Therapeutics and DNDi are collaborating to advance the clinical development of AN2-502998, an oral drug candidate with potential to cure chronic Chagas disease, which affects millions globally.
Clinical Trial Plans: Startup activities for a Phase 1 human study of AN2-502998 are underway, with a Phase 2 study expected to begin in 2026, aiming to provide a safer and more effective treatment option for Chagas disease.
See More
